NCT00209807

Effect of Escitalopram vs. Reboxetine on Gastro-intestinal Sensitivity of Patients With Major Depressive Disorder

Effect of Escitalopram vs. Reboxetine on Somatic and Visceral Sensitivity of Patients With Major Depressive Disorder: a Randomized, Double Blind Clinical Trial

• Status: Unknown
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 42 (estimated)
• Sponsor: Hospital Universitari Vall d'Hebron Research Institute · Academic / Other
• Sex: All
• Age: 18 Years – 64 Years
• Healthy volunteers: Accepted

Summary

Patients with major depressive disorder (MDD) commonly have many gastrointestinal complaints. Gastrointestinal pain is classified into 2 categories: visceral and somatic pain. The main aim of this study is to compare somatic and visceral sensitivity between healthy people and pateints with MDD. These two sensitivities will be assessed by the 2 following tests: standardized rectal distension and Transdermal transcutaneous electric nerve stimulation. Thereafter, patients with MDD will be randomly allocated to escitalopram or reboxetine. After 6 weeks of treatment, somatic and visceral sensitivity will be reassessed.

Conditions

• Major Depression
• Pain
• Abdominal Pain

Interventions

Type	Name	Description
DRUG	escitalopram	escitalopram 10 mg/d for 6 weeks
DRUG	Reboxetine	Reboxetine 8 mg/d for 6 weeks
OTHER	No intervention	This group of healthy volonteers will receive no drug and will be a healthy comparator.

Timeline

• Start date: 2005-09-01
• Primary completion: 2009-06-01
• Completion: 2011-04-01
• First posted: 2005-09-21
• Last updated: 2010-05-27

Locations

1 site across 1 country: Spain